ObjectiveTo systematically review the effect of intermittent fasting on type 2 diabetes mellitus. MethodsThe CNKI, WanFang Data, VIP, CBM, PubMed, Web of Science, The Cochrane Library and EMbase databases were electronically searched to collect randomized controlled trials (RCTs) on intermittent fasting intervention in the treatment of type 2 diabetes mellitus from inception to April 2022. Two reviewers independently screened the literature, extracted data, and evaluated the risk of bias of the included studies. The RevMan 5.4 software and Stata 17.0 software were used for meta-analysis. ResultsA total of 17 RCTs comprising 1 428 patients with type 2 diabetes mellitus were included. The results of meta-analysis showed that intermittent fasting improved body weight (WMD=−2.84, 95%CI −3.79 to −1.88, P<0.05), body mass index (BMI) (WMD=−1.07, 95%CI −1.52 to −0.61, P<0.05), glycosylated hemoglobin levels (SMD=−0.78, 95%CI −1.19 to −0.38, P<0.05), and fasting glucose levels (SMD=−0.65, 95%CI −1.01 to −0.3, P<0.05). ConclusionThe current evidence suggests that intermittent fasting improves body weight, BMI, glycated hemoglobin, and fasting blood glucose levels in patients with type 2 diabetes. Due to the limited quantity and quality of the included studies, more high-quality studies are needed to verify the above conclusion.
ObjectiveTo systematically review the efficacy of patient decision aids (PDA) in the selection of treatment modalities for end-stage renal diseases. MethodsThe PubMed, Web of Science, Embase, Cochrane Library, CBM, CNKI and VIP databases were electronically searched to collect randomized controlled trials (RCTs) related to the objectives from inception to March 2023. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. Quantitative and qualitative analysis was then performed. ResultsA total of 8 RCTs involving 1 544 patients were included. The systematic review results showed that PDA could improve patient knowledge, reduce patient decision-making conflict, and change patient decision-making discussion rate. ConclusionCurrent evidence shows that patients with end-stage renal diseases can benefit from PDA to improve their decision-making knowledge and reduce conflicts in their decisions, but its impact on the decision-making outcome index is limited.